Objective: The discovery of selective v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation as an oncogenic mutation in cutaneous malignant melanoma (MM) has changed the treatment paradigm for melanoma. Selective BRAF inhibitors have demonstrated response rates far higher than standard chemotherapeutic options. BRAF mutation analysis is usually performed on primary tumour tissue; however, no conclusive data are available on the concordance of test results between primary tumours and corresponding metastases. We assessed the concordance of BRAF mutation status in a study of 16 primary BRAFnative tumours and their corresponding lymph node metastases. Method: 16 patients with histologically confirmed nonmutated BRAF MM who underwent surgical resection of the primary tumour and positive selective lymph node biopsy or lymphadenectomy were included. Mutation status was determined by means of a realtime PCR assay (Cobas 4800 BRAF V600 Mutation Test, Roche Molecular Systems). Results: There was a 100 % concordance of the BRAF results in primary tumor and corresponding metastases in 16 analyzed pairs. Conclusion: Our findings show total concordance in BRAF status between primary BRAF native tumors and their paired metastases, and suggest that acquisition of BRAF V600 mutation in metastases from primary native tumors is a rare event.